Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

masitinib

MASITINIB AB SCIENCE

masitinib (MASITINIB AB SCIENCE) is a fibroblast growth factor receptor 3 inhibitor.

EMA: refused Antineoplastic and immunomodulating agents (L01) L01EX06
Patents linked 15
Pipeline programs 5
News articles 0
Drug details — masitinib
Class
Antineoplastic and immunomodulating agents (L01)
Route
—
Patents
15
Programs
5
Data quality
0.83
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

masitinib (MASITINIB AB SCIENCE) is a fibroblast growth factor receptor 3 inhibitor.

Key facts

INN masitinib
Brand MASITINIB AB SCIENCE
Mechanism Fibroblast growth factor receptor 3 inhibitor
Target Fibroblast growth factor receptor 3
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EX06

Mechanism of action

Fibroblast growth factor receptor 3 inhibitor

Primary target: Fibroblast growth factor receptor 3

Approval history

Authority Status Date
EMA refused —

Pipeline programs

Browse pipeline
  1. AB15003 Phase 3 · AB Science · Mastocytosis
  2. AB19001 Phase 3 · AB Science · Amyotrophic Lateral Sclerosis
  3. AB20009 Phase 3 · AB Science · Multiple Sclerosis
  4. AB23005 Phase 3 · AB Science · Amyotrophic Lateral Sclerosis
  5. AB20006 Phase 2 · AB Science · Mast cell activation syndrome

Related & competitor drugs

Browse all drugs
  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Related patents

Browse patents

  1. CA 3217490

    MASITINIB POUR LE TRAITEMENT DU CANCER DE LA PROSTATE RESISTANT A LA CASTRATION

    Expires Wed Nov 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. CA 3201259

    MASITINIB POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    Expires Wed Jun 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. CA 3174748

    UTILISATION DE MASITINIB POUR LE TRAITEMENT DE LA MALADIE A CORONAVIRUS 2019 (COVID-19)

    Expires Wed Oct 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. CA 3168610

    MASITINIB POUR LE TRAITEMENT D'UNE SOUS-POPULATION DE PATIENTS SOUFFRANT DE SCLEROSE EN PLAQUES

    Expires Wed Aug 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. EP 3831384

    VERWENDUNG VON MASITINIB ZUR BEHANDLUNG VON EOSINOPHILEM ASTHMA

    Expires Tue Jun 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2021099616

    MASITINIB POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE

    Expires Wed May 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. CA 3018635

    UTILISATION DE MASITINIB POUR LE TRAITEMENT D'UNE SOUS-POPULATION DE PATIENTS ATTEINTS DE SCLEROSE LATERALE AMYOTROPHIQUE

    Expires Wed Sep 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 2017119760

    USE OF MASITINIB FOR THE TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

    Expires Wed Apr 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2017072335

    UTILISATION DE MASITINIB ET D'AUTRES INHIBITEURS DE MASTOCYTE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

    Expires Wed Apr 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. CA 3000894

    TRAITEMENT DE LA MASTOCYTOSE SYSTEMIQUE GRAVE PAR LE MASITINIB

    Expires Wed Apr 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 2017020867

    USE OF MASITINIB FOR THE TREATMENT OF CROHN'S DISEASE

    Expires Wed Jan 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 2016175302

    MASITINIB FOR TREATING GASTRIC CANCER

    Expires Wed Jun 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2016096933

    MASITINIB COMBINÉ À UTILISER DANS LE TRAITEMENT DU CANCER DU SEIN

    Expires Wed Jun 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 2016128999

    MASITINIB FOR TREATING HEPATIC CANCER

    Expires Wed May 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 2016089368

    TREATMENT OF MASTOCYTOSIS WITH MASITINIB

    Expires Wed Mar 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is masitinib?

masitinib (MASITINIB AB SCIENCE) is a fibroblast growth factor receptor 3 inhibitor.

What is the brand name for masitinib?

MASITINIB AB SCIENCE is a marketed brand name for masitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.